Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025. The dividend will be paid on September 12, 2025, to all stockholders ...

Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. The announcement will be ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

May 23 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab has settled its lawsuit over Amgen Inc's (AMGN.O), opens new tab proposed biosimilar version of J&J's top-selling treatment Stelara for ...

Amgen must face lawsuit claiming it hid $10.7 billion tax bill By Jonathan Stempel September 30, 20242:52 PM PDTUpdated September 30, 2024 ...

The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor.

Topline The Federal Trade Commission announced Friday it had reached a settlement with Amgen Inc. over the biopharmaceutical firm’s $27.8 billion acquisition of Horizon Therapeutics, after the ...

Biotechnology company, Amgen, has announced that it has entered into a definitive agreement to acquire deCODE Genetics, a global leader in human genetics, for US $415 million. The all-cash ...

Amgen won FDA approval for a cancer immunotherapy made from a genetically modified form of the cold sore virus. Here's how the drug could contribute to the rapidly growing field of immuno-oncology.